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Abstract 
Lung transplant survival is limited by obliterative bronchiolitis (OB), but the mechanisms of OB 
development are unknown.  Previous studies in a mouse model of orthotopic lung transplantation 
suggested a requirement for IL-17.  We have used this orthotopic mouse model to investigate the 
source of IL-17A and the requirement for T cells producing IL-17A.  The major sources of IL-
17A were CD4+ T cells and γδ T cells.  Depletion of CD4+ T cells led to a significantly 
decreased frequency and number of IL-17A+ lymphocytes and was sufficient to prevent acute 
rejection and OB.  However, mice with STAT3-deficient T cells, which are unable to 
differentiate into Th17 cells, rejected lung allografts and developed OB similar to control mice. 
The frequency of IL-17A+ cells was not decreased in mice with STAT3-deficient T cells due 
mainly to the presence of IL-17A+ γδ T cells.  Deficiency of γδ T cells also did not affect the 
development of airway fibrosis.  Our data suggest that CD4+ T cells are required for OB 
development and expansion of IL-17A responses in the lung, while Th17 and γδ T cells are not 
absolutely required and may compensate for each other.   
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Introduction 
Lung transplantation is a valuable therapeutic option for patients with end-stage lung 
diseases.  The major obstacle limiting lung transplant survival and function is chronic lung 
allograft dysfunction (CLAD), with one of the major manifestations being obliterative 
bronchiolitis (OB) with fibrous obliteration of the airways (1).  Progressive airway injury 
mediated by ongoing alloimmune and nonalloimmune responses to the lung allograft is thought 
to be the precursor of subsequent graft fibrosis (2).  OB/BOS remains one of the major 
limitations to long term success of lung transplant with approximately 50% of lung transplant 
recipients affected by 5 years (3).   
Recently, IL-17 and T helper 17 (Th17) cells have been linked to OB/BOS development 
after lung transplantation (4).  Expression of IL-17 in the BAL positively correlated with OB in 
lung transplant recipients and Th17 cells were associated with OB/BOS in humans (5, 6).  Using 
a murine MHC minor mismatch orthotopic lung transplantation model, our group previously 
found that systemic IL-17A protein and mRNA levels were much higher in mice with OB 
compared to those without OB (7).  Furthermore, mice treated with an IL-17RA:Fc fusion 
protein had decreased cellular rejection scores and did not develop OB.  However, the cellular 
sources of IL-17A in OB have not been investigated in an intact orthotopic lung transplant 
model.  A major source of IL-17 is CD4+ T cells (Th17), but other cells are known to produce 
IL-17A including innate lymphocytes (8-11).   
In the present study, we have investigated the source and timing of IL-17A producing 
cells and their requirement to promote graft fibrosis and OB.  We reasoned that identifying 
particular subsets may allow the design of more targeted and effective therapies that have less 
unintended consequences.  Our results suggest CD4+ T cells are required for promoting the IL-
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17A response to transplant and the development of OB in this model.  In contrast, deficiency of 
either major IL-17A-producing subset, Th17 or γδ T cells alone is not sufficient to prevent 
airway fibrosis.  Each subset may be compensating for the lack of the other to produce IL-17 and 
induce airway fibrosis.       
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Materials and Methods 
Animals 
C57BL/6N (H-2b) and C57BL/10 (H-2b) mice were purchased from Harlan Laboratories 
(Indianapolis, IN).  C57Bl/6N.Stat3fl/fl.CD4-Cre (STAT3CD4-/-) mice were previously described 
(12, 13).  C57Bl/6J.TCRδ-/- mice were purchased from Jackson Laboratories (Bar Harbor, ME).  
Mice were housed under specific pathogen-free conditions in the animal care facility at Indiana 
University or University of Illinois at Chicago.  Male animals weighing 24-30g were used as 
both donors and recipients.  All experimental mouse protocols were reviewed and approved by 
the Indiana University School of Medicine and the University of Illinois at Chicago Institutional 
Animal Care and Use Committee 
Orthotopic lung transplant 
A mouse model of orthotopic minor histocompatibility antigen mismatch left lung transplant was 
used and has been previously described in detail (7).  
CD4 T cell depletion in vivo 
CD4+ T cells were depleted in vivo by injection of rat anti-mouse CD4 (GK1.5) monoclonal 
antibody (Bio-X-cell), 250 µg on days -2, 0 and twice per week after transplantation.  Untreated 
allografts or isotype treated wild-type recipients were used as controls. 
Histology 
Lungs were inflated via the trachea with 10% neutral buffered formalin solution (Sigma-Aldrich, 
Missouri, USA), followed by embedding in paraffin.  Tissue sections were prepared and stained 
with H&E or Masson’s trichrome stain.  Standard clinical criteria for scoring vascular lung 
rejection were used according to ISHLT guidelines and scoring was done blinded (14).  For the 
6 
 
severity of fibrosis an arbitrary scale was used (15).  Presence of OB lesions was also 
determined.   
Preparation of tissue 
Lung single cell suspensions were collected by digestion with collagenase I (Life Technologies). 
Lymph nodes (LN) or spleen were dissociated mechanically.  Single cell suspensions were 
treated with red blood cell lysis buffer (BioLegend).  
Flow cytometry 
Cells were stained with antibodies for CD4, CD8, TCRβ, TCR γδ, CD3, IL-17A, IFN- γ and 
NK1.1 (Biolegend) or CD1d tetramer (NIH Tetramer facility, Emory University). For staining of 
intracellular cytokines, cells were stained first with surface markers, fixed with formaldehyde 
and permeabilized prior to stimulation with PMA and ionomycin.  Cells were acquired on a 
LSRII (BD Biosciences) and data analysis was performed with Flowjo software (Tree Star, 
Ashland, OR).   
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, 
CA).  Differences were considered significant at P<0.05.  All data are expressed as mean ± 
(SEM). 
Additional material and methods can be found in the supplements. 
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Results 
IL-17A producing CD4+ T cells and IFNγ producing CD4+ and CD8+ T cells infiltrate lung 
allografts 
A minor mismatch model of orthotopic left lung transplantation using C57Bl/10 (B10) 
mice as donors and C57Bl/6 (B6) mice as recipients was used as previously described (7).   To 
further characterize the immune response to transplant in this model, we determined the 
frequency of CD4+ and CD8+ T cells infiltrating the lung at different time-points after transplant.  
On day 7 post-transplant, very few lymphocytes had infiltrated the lungs and the production of 
cytokines was minimal (data not shown).  Compared to B6→B6 syngeneic lung transplants, 
CD4+ and CD8+ T cells were increased at day 21 in B10→B6 lung allografts (Figure S1).  By 
day 28 post-transplant, the frequency of CD4+ and CD8+ T cells in the lung allografts was 
comparable to the syngeneic lung transplants.   
CD4+ T cells were found to be either IFN-γ+ or IL-17A+ and the frequency of both 
subsets of cytokine-producing cells was increased compared to syngeneic grafts peaking at Day 
21 (Figure 1A and B).  The frequency of IFN-γ+CD8+ T cells was also significantly increased in 
lung allografts and peaked at day 21 (Figure 1C and D).  Very few CD8+ T cells produced IL-
17A in either allografts or syngeneic grafts (Figure 1C).  However, the percentage of IL-17A+ 
cells was not completely accounted for by CD4+ T cells (Figure 1E).   Both IL-17A producing 
CD4+ and CD4-negative lymphocytes contributed to an increased frequency of IL-17A+ 
lymphocytes in lung allografts.  
γδ T cells and CD4+ T cells are the majority of IL-17A+cells in allografts 
We found that γδ T cells were the other major population of IL-17A producing 
lymphocytes in B10→B6 lung allografts (Figure 2A).  In B6→B6 syngeneic grafts, they were 
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the majority of IL-17A+ lymphocytes, as well as in the native right lungs (Figure 2A and data not 
shown).  In addition to CD4+ T cells and γδ T cells, we found a small proportion of non-T cells 
producing IL-17A, which were not NK cells, and are likely innate lymphoid cells (ILC) (Figure 
S2).  Among IL-17A+TCRβ+ T cells, CD4+ T cells were the majority of cells followed by CD4-
CD8- T cells (Figure S2).  CD8+, NK1.1+ or invariant NK T cells were not a major proportion of 
the IL-17A+ cells (Figure S2). 
The absolute number of total IL-17A+ lymphocytes was significantly increased only in 
B10→B6 allografts and not B6→B6 syngeneic grafts (Figure 2B).  In addition, the absolute 
numbers of IL-17A+ CD4+ T cells and IL-17A+γδ T cells were significantly higher in the 
allografts (Figure 2B).  The total number of γδ T cells was also significantly increased in 
allografts compared with syngeneic grafts (Figure 2B).  These data suggested that both CD4+ and 
γδ T cells were the major sources of IL-17A after lung transplant.  
Depletion of CD4+ T cells prevents chronic rejection and OB and affects expansion of IL-17A+ 
cells 
To determine if CD4+ T cells were necessary for cellular rejection and airway fibrosis 
after orthotopic lung transplant, recipient mice were treated with a CD4-depleting antibody.  On 
day 21 after transplant, allografts from CD4-depleted mice displayed a normal gross appearance, 
while untreated control allografts were grossly darker in color and shrunken in size (data not 
shown).  Remarkably, none of the CD4-depleted allografts developed OB, while 44% of control 
allografts developed OB-like lesions, a similar incidence to what was reported previously (7) 
(Table 1).  Based on established clinical rejection criteria, we observed either no acute rejection 
(grade A0) or minimal (grade A1) to mild acute rejection (grade A2) with a mean grade of A1 in 
the CD4-depleted allografts on day 21 (Figure 3).  Histological analysis of untreated control 
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allografts demonstrated mild (grade A1) to severe (A4) acute rejection with a mean score of A3 
(Figure 3).  In addition, CD4-depleted allografts developed very little fibrosis, while untreated 
control allografts had minimal (F1) to severe fibrosis (F4) with a mean score of moderate fibrosis 
(F3) (Figure 3).  These data provide evidence that CD4+ T cells play a crucial role in chronic 
rejection and OB development in the lungs of a minor mismatch model.   
In allografts depleted of CD4+ T cells, we found a decrease in all IL-17A+ cells when 
compared to control allografts.  The decrease was almost to the levels found in the native right 
lungs of the recipients (Figure 4A and B).  The majority of the IL-17A+ cells in the absence of 
CD4+ T cells were still T cells with a similar proportion of TCRβ+ T cells and γδ T cells as in the 
presence of CD4+ T cells (Figure S2).  The residual IL-17A+TCRβ+ were mostly CD8+ T cells 
(Figure S2).  Interestingly, CD4-depletion had an effect on both the total number of γδ T cells 
and the number of IL-17A+γδ T cells in the allografts (Figure 4D and F).  The frequency of γδ T 
cells and IL-17A+γδ T cell was not significantly affected (Figure 4C and D).  Thus, allo-reactive 
CD4+ T cells are necessary for the recruitment or expansion of γδ T cells and other IL-17A-
producing subsets during allograft rejection.     
STAT3 signaling in CD4+ T cells and Th17 are not required for OB development  
While CD4+ T cells were required for the cellular rejection and airway fibrosis in our 
model, we hypothesized that Th17 cells were the key CD4+ T cells for driving the rejection 
response.  STAT3 is the major transcription factor required for the initiation of Th17 
differentiation (12, 16, 17).  Previous studies found that mice with STAT3-deficient T cells did 
not develop Th17 immune responses in vivo (17-19) .  To test the hypothesis that STAT3 and 
Th17 were required for OB development, we used STAT3CD4-/- mice as recipients in our model.  
Prior to transplant, IL-17A+CD4+ T cells were almost undetectable in the lungs of un-
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manipulated mice consistent with prior studies (data not shown).  B10 lungs were transplanted 
into STAT3CD4-/- or littermate wild-type controls.  Left lung allografts from STAT3CD4-/- mice had 
virtually no IL-17A+ CD4+ T cells on day 21 after transplant (Figures 5A and B).  Similarly, 
mediastinal lymph node T cells from STAT3CD4-/- mice demonstrated almost no detectable IL-
17A+ CD4+ T cells (Figure S3).  Despite the lack of Th17 cells in the lungs and draining lymph 
nodes, STAT3CD4-/- mice developed OB lesions with 4 of 14 (28.5%) STAT3CD4-/-mice having 
evidence of OB (Figure 5C).  The incidence of OB in the littermate controls was 1 out of 10 
(10%).  Acute rejection scores in these mice were also comparable to the left lung allografts from 
littermate controls (Figure 5D).  There was no difference in the overall fibrosis scores between 
the STAT3CD4-/- mice and controls (Figure 5D).  Our data suggest that STAT3 expression by 
CD4+ T cells and differentiation to Th17 are not required for OB.  
Since IL-17A+ and IFNγ+ CD4+ T cells share a reciprocal relationship, we determined if 
STAT3CD4-/- allografts had augmented IFNγ+ CD4+ T cells, which may be compensating for the 
loss of Th17 (16, 20).  As expected, we found a significantly higher proportion of IFNγ+CD4+ T 
cells in the STAT3CD4-/- allografts as compared to WT allografts (Figure S4).  However, the 
absolute number of IFNγ+ CD4+ T cells remained similar between STAT3CD4-/- and WT allografts 
(Figure S4).  Expression of IFNγ, TGF-β, IL-6 and IL-10 were also not altered in STAT3CD4-/- 
allografts (Figure S4).   
IL-17A production by γδ T cells in the absence of Th17  
Since airway fibrosis and OB developed in the left lung allografts in STAT3CD4-/- mice, 
the loss of IL-17A production from CD4+ T cells was possibly compensated for by γδ T cells or 
other cells.  However, previous work had suggested that γδ T cells may be unable to develop into 
IL-17A producing cells in the absence of Th17 cells (21).  Interestingly, the overall percentage of 
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IL-17A+ cells was no different between STAT3CD4-/- recipients compared to WT recipients 
(Figure 6A and B).  In STAT3CD4-/- recipients the predominant population of IL-17A+ cells was 
γδ T cells and the absolute number of IL-17A+ γδ T cells remained comparable between wild-
type and STAT3 CD4-/- recipients (Figure 6C and D).  The mediastinal lymph nodes also had no 
decrease in the frequency of IL-17A+ cells in STAT3CD4-/- mice and γδ T cells were the major cell 
type (Figure S3).  While there was no difference in frequency, a significant decrease in the 
number of IL-17A+ cells was found in the lung allografts of STAT3CD4-/- mice (Figure 6B).   
Thus, in the absence of STAT3 expression by CD4+ T cells, γδ T cells are the majority source of 
IL-17A in lung allografts and IL-17A+ γδ T cells are unaffected by the lack of Th17 
differentiation.    
γδ T cells are not necessary for OB development 
Our data suggested that γδ T cells may participate in OB development through production 
of IL-17A.  Earlier studies found that γδ T cell deficiency was associated with prolonged survival 
of cardiac allografts (22, 23).  To determine whether γδ T cells were required for OB 
development, TCRδ-/- mice were used as recipients.  However, there was no apparent effect on 
cellular rejection or fibrosis in the absence of γδ T cells (Figure 7A and B).  TCRδ-/- recipients 
developed OB-like lesions similar to TCRδ+/- controls with 3 out of 11 TCRδ-/- mice (27.2%) 
developing OB compared to 2 of 8 mice (25%) developing OB in the controls.  In the absence of 
γδ T cells, the majority of IL-17A+ cells were CD4+ T cells in the lung allografts and the native 
lungs (Figure 7C).  At the time of sacrifice, we did not find evidence of residual donor γδ T cells 
in the lungs (data not shown).  As with the STAT3CD4-/- mice, TCRδ-/- allografts had a frequency 
of IL-17A+ cells similar to WT recipients (Figure 7D).  These data suggest IL-17A production is 
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compensated for by CD4+ T cells in the absence of γδ T cells and γδ T cells are not absolutely 
required for cellular rejection and the development of OB in this model.  
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DISCUSSION  
In the current study, we investigated the requirement for IL-17 producing T cells to 
mediate chronic rejection and the development of OB in a mouse lung transplant model 
previously found to be ameliorated by IL-17 neutralization (7).  We found that CD4+ T cells 
were required for rejection and fibrosis, as depletion of CD4+ T cells significantly decreased the 
severity of cellular infiltration, the lung IL-17A response, and prevented the development of OB 
in the mouse.  While CD4+ IL-17A+ T cells were significantly increased in lung allografts, Th17 
cells were not required for rejection and the development of OB.  In the absence of Th17, γδ T 
cells were the major IL-17A producing population in lung allografts.  However, γδ T cell-
deficient mice developed airway fibrosis and an IL-17A cellular response in the lungs similar to 
wild-type recipients.  In the absence of γδ T cells, the IL-17A response appears to be 
compensated for by CD4+ T cells.  Our data suggest CD4+ T cells are required to promote the IL-
17A+ immune response, cellular rejection and airway fibrosis in mouse lung allografts.  
Targeting either of the major IL-17A producing cells, Th17 or γδ T cells alone, is not sufficient 
to affect rejection and fibrosis after lung transplant.  
The absence of direct allo-recognition in the minor mismatch model, which is important 
for CD8+ T cell activation, is likely the reason for the requirement for CD4+ T cells (24).  In 
contrast, CD8+ T cells alone were sufficient to induce rejection in a major mismatch model of 
orthotopic lung transplant (25).  Interestingly, we found that in the absence of CD4+ T cells, 
there was a reduction in the IL-17A response, mainly IL-17A+γδ T cells, in the allografts.  The 
overall γδ T cell response was also diminished after CD4+ T cell depletion.  Our data suggest that 
alloreactive CD4+ T cells are promoting expansion of the innate γδ T cell response and other IL-
17A-producing cells during allograft rejection.  In an acute lung injury model, CD4+TCRβ+ T 
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cells were also found to promote γδ T cell recruitment and production of IL-17A (26).  Our data 
are consistent with this work and support a role for allo-reactive CD4+ T cells in expanding or 
recruiting innate IL-17A producing cells through cytokine and chemokine production either 
directly or indirectly from CD4+ T cells.   
Since CD4+ T cells were a major source of IL-17A and Th17 cells had previously been 
linked to human OB, we expected that CD4+ T cell differentiation to Th17 would be required for 
the development of OB (5, 6).  Contrary to our expectations, conditional deletion of STAT3 in 
CD4+ T cells did not affect cellular rejection or the development of OB.  It is unlikely that there 
is significant residual IL-17A production from CD4+ T cells, as CD4+ T cells from the lungs or 
lymphoid tissue of un-manipulated or post-transplant STAT3CD4-/- mice did not produce IL-17A 
when stimulated ex vivo.  Further, these mice have been used by others to evaluate Th17 
responses in vivo without evidence of IL-17A production by CD4+ T cells (17, 19).  We also did 
not find evidence of a donor source.  In the absence of Th17, we did not find a significant 
increase in the number of IFN-γ+CD4+ T cells in STAT3CD4-/- mice recipients. We also found no 
significant difference in expression of IFN-γ, IL-6, TGFβ or IL-10.  These data suggest there is 
not a major expansion of Th1 or these other cytokines compensating for the loss of STAT3 in the 
T cells. In addition to affecting IL-17A production, STAT3 expression by CD4+ T cells is 
necessary for production of the cytokines IL-17F, IL-21 and IL-22 (12).  The Th17 lineage in 
general does not appear to be required for mediating OB in this model.  
γδ T cells were the predominant source of IL-17A in the absence of Th17 cells. The 
defects in the STAT3CD4-/- mice are restricted to αβ T cells and would not affect STAT3 
expression in γδ T cells (27).  However, we were surprised to find an intact IL-17A γδ T cell 
response in the absence of Th17 cells, as a recent study suggested that Th17 cells were required 
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for the maintenance of IL-17-producing γδ T cells in vivo in a TGF-β dependent manner (21).  
Instead, we found that γδ T cells from the lungs or draining lymph nodes had no defect in IL-
17A production either in un-manipulated mice (unpublished data) or after transplant in the 
absence of Th17.  It is possible STAT3CD4-/- T cells produce enough TGF-β to support 
maintenance of IL-17A+γδ T cells during homeostasis.    
In the TCRδ-/- recipients, we found that fibrosis and OB was not decreased compared to 
controls.  We did not use antibody depletion of γδ T cells, as the antibodies have been found to 
be non-depleting in vivo and may be activating γδ T cells (28, 29).   However, we did not find 
residual γδ T cells to suggest expansion of donor γδ T cells was confounding our results.  
Instead, CD4+ T cells appeared to compensate for the lack of IL-17A+γδ T cells, as the frequency 
of IL-17A+ cells in the lungs was similar to wild-type mice.  Thus γδ T cells are not absolutely 
required as a source of IL-17A to promote OB in this model and the cells producing IL-17A 
appear to be able to respond to deficiency of other subsets.    
Interestingly, we found differences in the prevalence of OB-like pathology in wild-type 
littermates of STAT3CD4-/- mice, bred in house on a C57Bl/6N background, compared to mice 
purchased from Harlan Labs.  The previous study with this model found a similar incidence of 
OB, also using C57Bl/6N mice from Harlan Labs (7).  However, a recent study did not find 
evidence of OB using C57Bl/10 lung transplanted to C57Bl/6J mice from Jackson labs (30).  We 
also found the TCRδ-/- mice from Jackson and TCRδ+/- mice, mixed C57Bl/6N and C57Bl/6J 
background, had a decreased incidence of OB at 25%, although we still found similar pathology 
to the previous study (7). The different results may be due to differences in microbiota or 
differences in genetic background between the strains.  Procedural and technical variations also 
cannot be ruled out.  An important caveat in our model is that the airway fibrosis pattern differs 
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from the constrictive OB that can be found in humans after lung transplant.  The pathology in our 
model includes fibrous plugs, with loss of overlying epithelium and only partial airway 
obliteration (7, 31).  Nevertheless, the model allows an understanding of the processes by which 
the alloreactive immune response and IL-17A can promote fibrosis after lung transplant without 
the need for immunosuppression as in a full mismatch model (32).  
Previously it was found that blockade of IL-17 using IL-17R:Fc protein abrogated OB 
(7).  We have expanded on these data and find that graft infiltrating IL-17A+ cells are largely 
CD4+ Th17 cells and γδ T cells.  A minor subset was TCRβ+CD4-CD8- T cells, which may be 
Type II NKT cells that do not recognize the CD1d tetramer used, or they may have lost 
expression of CD4 or CD8 (10).  While these other cells can produce IL-17A, CD4+ and γδ T 
cells were the predominant populations found in wild-type mice and were increased in the lung 
after transplant.   The absence of either Th17 or γδ T cells did not protect from airway fibrosis or 
OB in this model.  These data are consistent with findings in a tracheal transplant mouse model 
that suggested redundancy for IL-17A production from CD4+ T cells and γδ T cells (33).  In 
addition, we have found a role for CD4+ T cells in the recruitment or expansion of γδ T cells and 
other IL-17A+ cells in the lung.  However, we have also found that Th17 or γδ T cells are 
compensatory sources of IL-17A when the other T cell subset is deficient.  These data suggest 
that IL-17A-producing cells respond to similar signals and may co-regulate each other.  Others 
have proposed that IL-17 regulates the homeostasis of IL-17+γδ T cells during development and 
our work suggests the regulation extends to an inflammatory response (34).  In conclusion, our 
data support a model where CD4+ T cells initiate the alloimmune response to minor antigens and 
promote airway fibrosis.  Absence of CD4+ T cells diminishes the IL-17A+ cell response during 
allograft rejection and the expansion of γδ T cells.  Targeting CD4+ T cells early after transplant 
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may prevent the development of deleterious IL-17 responses.  A better understanding of the 
signals that regulate IL-17 producing cells may lead to novel therapies to improve outcomes after 
lung transplantation.   
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Figure Legends 
Figure 1. IL-17A and IFN-γ producing T cells are increased in allografts. Transplanted lungs 
from B6→B6 and B10→B6 transplants were harvested at different time-points and analyzed by 
flow cytometry. (A) Representative flow cytometry plots with frequency of IL-17A+ and IFN-γ+ 
populations (right plot) gated on CD4+ T cells (left plot). (B) Frequency of IL-17A+ and IFN-γ+ 
CD4+ T cells in lymphocytes gated by size. (C) Representative dot plots with frequency of IL-
17A+ and IFN-γ+ populations (right) gated on CD8+ T cells (left). (D) The overall frequency of 
IFN-γ+ CD8+ T cells in lymphocyte gate. (E) Percentage of IL-17A+ cells (left) and non-CD4 IL-
17A+ cells (right) in lymphocyte gate. Number in dot plots represents percentage. For day 14 (n = 
2 for B6→B6, n = 4 for B10→B6); day 21 (n = 5 for B6→B6, n = 12 for B10→B6) and day 28 
(n = 3 for B6→B6, n = 5 for B10→B6). For IFN-γ+CD4+ and IFN-γ+CD8+ T cells, n=4 for 
B6→B6 at day 21.  Data were analyzed by unpaired t test compared to B6→B6 at same time-
point, *P<0.05, **P<0.01.   
Figure 2. Increased IL-17A+ cells in allografts are CD4+ T cells and γδ T cells. Transplanted 
lungs from B6→B6 and B10→B6 transplants were harvested at day 21 post-transplant and 
analyzed by flow cytometry. (A) Representative dot plots indicating frequency of IL-17A+ cells 
(left) of total lymphocytes and frequency of CD4+ T cells and γδ T cells (right) in IL-17A+ 
lymphocytes in transplanted left lung.  (B) The absolute numbers of IL-17A+ lymphocytes, IL-
17A+CD4+ T cells, IL-17A+γδ T cells and total γδ T cells in transplanted left lung. Absolute 
number of cells is normalized to the weight of the lung.  For IL-17A+ cells and IL-17A+CD4+ T 
cells, n=5 for B6→B6, n=12 for B10→B6; for IL-17A+γδ T cells and total γδ T cells, n=4 for 
B6→B6, n=9 for B10→B6; data analyzed by Mann-Whitney U test, ** P<0.01.  
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Figure 3.  CD4+ T cells are required for rejection and the development of OB.  B6 recipients 
of B10 left lungs were treated with CD4-depleting mAb (GK1.5) two days prior to transplant and 
twice a week post-transplant, lungs were harvested and analyzed on Day 21. Untreated B10→B6 
allografts were used as control. (A) H&E  and Masson’s trichrome  staining of lung sections with 
no evidence of rejection in anti-CD4 treated allografts  (middle panels) compared to cellular 
rejection and OB (arrow) found in the control allografts (left panels), an anti-CD4 treated 
allograft with mild cellular rejection and fibrosis has also been shown (right panels). 
magnification, 10X and 20X.  (B) Acute rejection (A) scores and fibrosis (F) scores in 
transplanted left lung as described in methods, n=39 (control) and n=15 (anti-CD4), ***P<0.001 
with Mann-Whitney U test. H&E, hematoxylin and eosin. 
Figure 4. CD4+ T cell depletion decreases IL-17A and γδ T cell response to lung transplant.  
B6 recipients of B10 left lungs were treated with CD4-depleting mAb (GK1.5) two days prior to 
transplant and twice a week post-transplant, lungs were harvested and analyzed on Day 21. 
Isotype antibody treated B10→B6 allografts were used as control. (A) Representative dot plots 
showing frequency of IL-17A+ cells of total lymphocytes in transplanted left lungs. (B) 
Frequency and absolute number of IL-17A+ lymphocytes of total lymphocytes in transplanted 
left lungs. (C) Dot plots representing frequency of γδ T cells on gated lymphocytes. (D) 
Frequency and absolute number of γδ T cells of total lymphocytes in the transplanted left lungs. 
(E) Representative dot plots indicating proportion of IL-17A+ γδ T cells after CD4+ T cell 
depletion on lymphocyte size gate. (F) Frequency and absolute number of IL-17A+ γδ T cells in 
the transplanted lungs. Unpaired t test for frequency and Mann-Whitney U test for absolute 
number, *P<0.05, **P<0.01, n=7 (control), n=8 (anti-CD4). The absolute number of cells has 
been normalized to the weight of the lung. 
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Figure 5. STAT3 expression in CD4+ T cells is not required for OB development.  Left lungs 
from B10 mice were transplanted into STAT3fl/flCD4-Cre negative (WT) or STAT3CD4-/- 
littermates and analyzed at day 21 post-transplant.  (A) Representative dot plots for intracellular 
staining for IL-17A+ lung lymphocytes in transplanted allografts, gated on lymphocyte size, 
percentage of cells noted in quadrants. (B) Frequency (top) and absolute number (bottom) of IL-
17A+CD4+ T cells of total lymphocytes in the native and transplanted left lungs, absolute number 
normalized to the weight of the lung, n=6 for WT, n=7 for STAT3CD4-/-, analyzed by Mann-
Whitney U test, **P<0.005.  (C) H&E (top) and Masson’s trichrome (bottom) staining 
demonstrated the presence of OB-like lesions (arrows) in transplanted left lungs from WT and 
STAT3CD4-/- mice, magnification, 20X. (D) Acute rejection (A) scores and fibrosis (F) scores in 
left lung allografts as described in Methods, n=10 (WT), n=14 (STAT3CD4-/-).  
Figure 6. IL-17A is primarily produced by γδ T cells in absence of TH17 in STAT3CD4-/- 
mice. As in Figure 4, transplanted left lungs and native lungs were analyzed at day 21 post-
transplant.  (A) Representative dot plots showing percentage of IL-17A+ lymphocytes on gated 
lymphocytes from WT and STAT3CD4-/- mice. Number in dot plots indicates percentage. (B) 
Percentage and absolute number of IL-17A+ lymphocytes in right and transplanted left lungs 
gated on lymphocytes, analyzed using Mann-Whitney U test, *P<0.05, **P <0.01. (C) Dot plots 
showing analysis percentage of γδ T cells in the IL-17A+ population in the lung. Number in the 
dot plots indicates percentage.  (D) Frequency of γδ T cells in the IL-17A+ population and 
absolute number of IL-17A+γδ T cells; one-way ANOVA with post hoc Newman-Keuls multiple 
comparison test for frequency and Mann-Whitney U test for absolute number, *P<0.05, 
**P<0.01, ***P<0.001  n=6 for WT, n=7 for STAT3CD4-/-. Data on absolute number of cells are 
presented after normalization to the weight of the lung.  
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Figure 7.  γδ T cell-deficiency does not prevent OB.  Left lungs from B10 mice were 
transplanted into TCRδ-/- or TCRδ+/- mice and analyzed at day 21 post-transplant. (A) H&E (top) 
and Masson’s trichrome (bottom) stained lung allografts from TCRδ+/- and TCRδ-/- mice 
demonstrated OB-like lesions (arrows) in the airway, magnification, 20X.  (B) Analysis of acute 
rejection (A) scores and fibrosis (F) scores in left lung allografts as described in methods, n=8 
(TCRδ+/-), n=11 (TCRδ-/-). (C) Representative dot plots showing percentage of IL-17A+ 
lymphocytes on gated lymphocytes (left) and percentage of CD4+TCRβ+ T cells of IL-17A+ 
lymphocytes (right) in native lungs and transplanted left lungs from TCRδ-/- mice (n=5).  (D)  
Frequency of IL-17A+ lymphocytes in transplanted left lungs from wild-type mice (n=7) as in 
Figure 4 and TCRδ-/- mice. 
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Supporting information 
Additional Supporting Information may be found in the online version of this article. 
Figure S1. CD4+ and CD8+ T cells are increased in allografts. Transplanted lungs from 
B6→B6 and B10→B6 transplants were harvested at different time-points and analyzed by flow 
cytometry.  (A) Frequency of CD4+ and (B) frequency of CD8+ T cells in the lymphocyte gate in 
the transplanted left lung at days 14 (n = 2 for B6→B6; n = 4 for B10→B6), 21 (n = 5 for 
B6→B6; n = 12 for B10→B6) and 28 (n = 3 for B6→B6; n = 5 for B10→B6) post-transplant, 
compared to B6 → B6, analyzed by unpaired t test, **P < 0.01.   
Figure S2. Characterization of IL-17A producing cells in lung allografts. Left lungs from 
B10 mice were transplanted into untreated, anti-CD4 antibody or isotype treated B6 recipients 
and were analyzed at Day 21 post-transplant by flow cytometry. (A) Representative dot plots of 
isotype antibody treated control lung allograft showing percentage of different IL-17A producing 
cellular subsets on gated IL-17A+ lymphocytes. (B) Representative dot plots of an untreated 
allograft depicting proportion of iNKT cells (TCRβ+ PBS57/CD1d tetramer+) on gated IL-17A+ 
lymphocytes; n=3. (C) The stacked bar graph indicating average proportion of different cell 
types on gated IL-17A+ lymphoyctes in anti-CD4 antibody and control isotype antibody treated 
lung allografts; n=6 (control), n=7 (anti-CD4) except for γδ+ T cells of IL-17A+ lymphoyctes 
where n=7 (control), n=8 (anti-CD4).  
Figure S3. Mediastinal lymph nodes of STAT3CD4-/- mice are deficient in Th17 cells and IL-
17A+ lymphocytes are mainly γδ T cells. Left lungs from B10 mice were transplanted into 
STAT3fl/flCD4-Cre negative (WT) or STAT3CD4-/- littermates and mediastinal lymph nodes were 
analyzed at Day 21 post-transplant by flow cytometry. (A) Representative dot plots showing IL-
17A producing CD4+ T cells when gated on total lymphocytes in mediastinal lymph nodes from 
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the transplanted WT and STAT3CD4-/- animals. Number in quadrants represents percentage of 
cells. (B) Frequency of IL-17A producing CD4+ T cells in mediastinal lymph nodes when gated 
on total lymphocytes in transplanted mice. **P<0.005 (Mann-Whitney U test). (C) 
Representative dot plots showing percentage of IL-17A expressing cells on gated lymphocytes in 
mediastial lymph nodes. (D) The frequency of IL-17A producing cells in mediastinal lymph 
nodes as assessed by flow cytometry when gated on lymphocytes. (E) Dot plots showing analysis 
of γδ T cells on gated IL-17A cells in lymph node at day 21 of transplant. (F) Percentage of γδ T 
cells of IL-17A+ lymphocytes. ***P<0.0001 (unpaired t-test). (A, C, E) The number in dot plots 
indicates percentage. (B, D, F) n=6 for WT and STAT3CD4-/-.  
Figure S4. STAT3 deficient CD4+ T cells are skewed towards Th1 phenotype. Left lungs 
from B10 mice were transplanted into STAT3fl/fl.CD4-Cre negative (WT) or STAT3CD4-/- 
littermates and analyzed at day 21 post-transplant. (A) Representative dot plots showing 
percentage of IFNγ+ lymphocytes on gated CD4+ T cells in native and transplanted lung from 
WT and STAT3CD4-/- mice. Number in dot plots indicates percentage. (B) Percentage and 
absolute number of IL-17A+CD4+ T (Th1) cells, absolute number normalized to the weight of the 
lung, one-way ANOVA with post hoc Newman-Keuls multiple comparison test was used for 
analysis, *P<0.05, **P<0.01, ***P<0.001, n=6 for WT, n=7 for STAT3CD4-/-. (C) Relative 
mRNA expression of indicated genes in transplanted lungs as quantified using Real Time PCR. 
Data are plotted relative to WT and normalized to β-actin. Analyzed using Mann-Whitney U test, 
n=4 for WT, n=8 for STAT3CD4-/-. 
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Figure S1. CD4+ and CD8+ T cells are increased in allografts. Transplanted lungs from 
B6→B6 and B10→B6 transplants were harvested at different time-points and analyzed by flow 
cytometry.  (A) Frequency of CD4+ and (B) frequency of CD8+ T cells in the lymphocyte gate in 
the transplanted left lung at days 14 (n = 2 for B6→B6; n = 4 for B10→B6), 21 (n = 5 for 
B6→B6; n = 12 for B10→B6) and 28 (n = 3 for B6→B6; n = 5 for B10→B6) post-transplant, 
compared to B6 → B6, analyzed by unpaired t test, **P < 0.01.   
Figure S2. Characterization of IL-17A producing cells in lung allografts. Left lungs from 
B10 mice were transplanted into untreated, anti-CD4 antibody or isotype treated B6 recipients 
and were analyzed at Day 21 post-transplant by flow cytometry. (A) Representative dot plots of 
isotype antibody treated control lung allograft showing percentage of different IL-17A producing 
cellular subsets on gated IL-17A+ lymphocytes. (B) Representative dot plots of an untreated 
allograft depicting proportion of iNKT cells (TCRβ+ PBS57/CD1d tetramer+) on gated IL-17A+ 
lymphocytes; n=3. (C) The stacked bar graph indicating average proportion of different cell 
types on gated IL-17A+ lymphoyctes in anti-CD4 antibody and control isotype antibody treated 
lung allografts; n=6 (control), n=7 (anti-CD4) except for γδ+ T cells of IL-17A+ lymphoyctes 
where n=7 (control), n=8 (anti-CD4).  
Figure S3. Mediastinal lymph nodes of STAT3CD4-/- mice are deficient in Th17 cells and IL-
17A+ lymphocytes are mainly γδ T cells. Left lungs from B10 mice were transplanted into 
STAT3fl/flCD4-Cre negative (WT) or STAT3CD4-/- littermates and mediastinal lymph nodes were 
analyzed at Day 21 post-transplant by flow cytometry. (A) Representative dot plots showing IL-
17A producing CD4+ T cells when gated on total lymphocytes in mediastinal lymph nodes from 
the transplanted WT and STAT3CD4-/- animals. Number in quadrants represents percentage of 
cells. (B) Frequency of IL-17A producing CD4+ T cells in mediastinal lymph nodes when gated 
on total lymphocytes in transplanted mice. **P<0.005 (Mann-Whitney U test). (C) 
Representative dot plots showing percentage of IL-17A expressing cells on gated lymphocytes in 
mediastial lymph nodes. (D) The frequency of IL-17A producing cells in mediastinal lymph 
nodes as assessed by flow cytometry when gated on lymphocytes. (E) Dot plots showing analysis 
of γδ T cells on gated IL-17A cells in lymph node at day 21 of transplant. (F) Percentage of γδ T 
cells of IL-17A+ lymphocytes. ***P<0.0001 (unpaired t-test). (A, C, E) The number in dot plots 
indicates percentage. (B, D, F) n=6 for WT and STAT3CD4-/-.  
Figure S4. STAT3 deficient CD4+ T cells are skewed towards Th1 phenotype. Left lungs 
from B10 mice were transplanted into STAT3fl/fl.CD4-Cre negative (WT) or STAT3CD4-/- 
littermates and analyzed at day 21 post-transplant. (A) Representative dot plots showing 
percentage of IFNγ+ lymphocytes on gated CD4+ T cells in native and transplanted lung from 
WT and STAT3CD4-/- mice. Number in dot plots indicates percentage. (B) Percentage and 
absolute number of IL-17A+CD4+ T (Th1) cells, absolute number normalized to the weight of the 
lung, one-way ANOVA with post hoc Newman-Keuls multiple comparison test was used for 
analysis, *P<0.05, **P<0.01, ***P<0.001, n=6 for WT, n=7 for STAT3CD4-/-. (C) Relative 
mRNA expression of indicated genes in transplanted lungs as quantified using Real Time PCR. 
Data are plotted relative to WT and normalized to β-actin. Analyzed using Mann-Whitney U test, 
n=4 for WT, n=8 for STAT3CD4-/-. 
 
 




Supplemental Materials and Methods 
Animals  
Adult male C57BL/6N (H-2b) and C57BL/10 (H-2b) mice were purchased from Harlan 
Laboratories (Indianapolis, IN).  Stat3fl/fl mice with a CD4-Cre transgene (designated as 
STAT3CD4-/-) (H-2b) mice were previously described on a C57Bl/6N background (15, 16).  
Stat3fl/fl littermates negative for the CD4-Cre transgene were used as wild-type (WT) controls in 
experiments with STAT3CD4-/- mice.  γδ T cell deficient mice (TCRδ-/-) on C57Bl/6J background 
were obtained from Jackson Laboratories (Bar Harbor, ME) and TCR δ-/+ were generated by 
breeding with C57Bl/6N from Harlan labs.  Mice were housed under specific pathogen-free 
conditions in the animal care facility at Indiana University or University of Illinois at Chicago.  
Male animals, 8–12 weeks of age weighing 24-30g, were used as both donors and recipients. All 
experimental mouse protocols were reviewed and approved by the Indiana University School of 
Medicine Institutional Animal Care and Use Committee and the University of Illinois at Chicago 
Animal Care Committee. 
Orthotopic lung transplant 
A mouse model of orthotopic minor histocompatibility antigen mismatch left lung transplant was 
used and has been previously described in detail (10). The entire operation was performed using 
a Prescott's operating microscope (Zeiss 6SFC, Monument, USA) with 20-40× magnification.  
All surgical procedures were performed utilizing sterile technique.  Mice were not treated with 
antibiotics or immunosuppressive agents.  Both donor and recipient were anesthetized with 
Isoflurane.  
Histology 
Lungs were inflated via the trachea with 10% neutral buffered formalin solution (Sigma-Aldrich, 
Missouri, USA), followed by embedding in paraffin.  Tissue sections were prepared and stained 
with H&E or Masson’s trichrome stain.  Standard clinical criteria for scoring vascular lung 
rejection were used according to ISHLT guidelines and scoring was done blinded (17).  For the 
severity of fibrosis an arbitrary scale was used with F1= normal; F2= mild fibrosis, F3= 
moderate fibrosis, F4=severe fibrosis (18).  Presence of OB lesions was also determined.  For 
transplanted lungs, 2/3 of the lung was used for histology and the remaining 1/3 was used for 
flow cytometry.  As a control, the upper and middle lobes from the native right lungs were used 
for histology or flow cytometry.  
Flow cytometry 
For cell surface staining, cells were stained with antibodies for CD4, CD8, TCRβ, TCR γδ, and 
NK1.1 in FACS buffer (0.01% NaN3 + 2% FBA in 1X PBS) for 30 min at 4°C.  Cells were 
stained with PBS57-loaded CD1d tetramer (NIH Tetramer facility, Emory University) for 
identification of invariant NKT (iNKT) cells. For staining of intracellular cytokines, cells were 
stained with surface markers, fixed with 2% formaldehyde and permeabilized with 0.5% saponin 
buffer. After permeabilization, cells were stimulated with PMA (100 ng/ml; Sigma), ionomycin 
(1 μg/ml; Sigma) for 4 hours and Brefeldin A (10 µg/ml; Sigma) was added for last 3 hours. 
Cells were then stained with antibodies for IL-17A, IFN- γ and respective isotype controls.  The 
stained cells were acquired on a LSRII (BD Biosciences) and data analysis was performed with 
Flowjo software (Tree Star, Ashland, OR). The absolute number of cells has been adjusted for 
the weight of the lung tissue, as only a portion of lung is used for flow cytometry. All antibodies 
were obtained from BioLegend. 
Statistical analysis 
Statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, 
CA).  For comparison of two groups with normal distribution, two-tailed unpaired t test was 
used.  One-way ANOVA with post hoc Newman-Keuls test was applied for comparisons 
between multiple groups with normal distribution.  For skewed data, Mann-Whitney U test was 
applied. The prevalence of OB between different groups in Table 1 was compared using two-
tailed Fisher’s exact test. Differences were considered significant at P<0.05.  All data are 
expressed as mean ± (SEM). 
 
